May 23, 2006 Foundation Announces Collaboration on Clinical Trial Targeting Cardiovascular Risks Patient Enrollment Efforts Target At-Risk African Americans

 

PRESS RELEASE 

For Immediate Release Contact: Cleve Mesidor (202) 223-7560

May 23, 2006 (202) 277-7381 cell

Foundation Announces Collaboration on 

Clinical Trial Targeting Cardiovascular Risks 

Patient Enrollment Efforts Target At-Risk African Americans 

Washington, DC – The National Minority Health Month Foundation (The Foundation) and deCODE Genetics, Inc. announced today a collaborative effort to support patient enrollment in the Leukotrienes in African American Patients with Coronary Artery Disease trial (LTCAD study). This multi-center trial is unique by focusing on a subgroup of patients with prior unstable angina or acute MI who have the highest identifiable risk of heart attack. Recent research suggest that some patients of a combined African and European lineage carry a variant of the gene encoding leukotriene A4 hydrolase (LTA4 hydrolase) that puts them at a three-fold greater risk for a heart attack. DG-031, licensed by deCODE Genetics, Inc. is designed to block the negative effects of the variant gene. The LTCAD study will examine the long-term safety and efficacy of DG-031. The trial is being conducted under a Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA).  Read more